CClinicalTrials.gg
CompletedNCT06936098Updated Apr 20, 2025

Deep Learning-Based Analysis of Colorectal Cancer Pathology Images: An Innovative Approach for Predicting Colorectal Cancer Subtypes

An observational study in Colorectal Liver Metastasis (CRLM), Histopathological Growth Patterns (HGPs) and Artificial Intelligence (AI) in Diagnosis, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-20.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
431
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Colorectal cancer (CRC) is a leading cause of mortality in China, with metastasis significantly contributing to poor outcomes. Histopathological growth patterns (HGPs) in colorectal liver metastasis (CRLM) provide vital prognostic insights, yet the limited number of pathologists highlights the need for auxiliary diagnostic tools. Recent advancements in artificial intelligence (AI) have demonstrated potential in enhancing diagnostic precision, prompting the development of specialized AI models like COFFEE to improve the classification and management of HGPs in CRLM patients. This study aims to develop and validate a Transformer-based deep learning model, COFFEE, for the classification of colorectal cancer subtypes using whole slide images (WSIs) from patients diagnosed with colorectal cancer liver metastasis. The model is pre-trained using self-supervised learning (DINO) on WSIs from the TCGA-COAD cohort, utilizing a Vision Transformer (ViT) architecture to extract 384-dimensional feature vectors from 256×256 pixel patches. The COFFEE model integrates a Transformer-based Multiple Instance Learning (TransMIL) framework, incorporating multi-head self-attention and Pyramid Position Encoding Generator (PPEG) modules to aggregate spatial and morphological information. The study includes training, testing, and prospective validation cohorts and evaluates the performance of the model in both binary and multi-class classification settings, as well as its potential to assist pathologists in clinical workflows.

02

Conditions studied

  • Colorectal Liver Metastasis (CRLM)
  • Histopathological Growth Patterns (HGPs)
  • Artificial Intelligence (AI) in Diagnosis
  • Vision Transformer (ViT)
  • Desmoplastic Classification
03

In context

Neoplasm Metastasis

3,517 studies on the registry are indexed under Neoplasm Metastasis; 885 are open to participants now.

This study's enrollment of 431 is above the median of 121 across 594 observational studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 466 studies on the registry; 271 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study involved 431 patients with colorectal cancer liver metastasis, all undergoing surgery at the Sixth Affiliated Hospital of Sun Yat-sen University. The cohort consisted of 297 patients in the training set and 104 patients in the testing set.

Inclusion criteria

  1. Patients diagnosed with colorectal cancer liver metastasis (CRLM) undergoing surgical treatment;
  2. The maximum diameter of resected metastatic lesions should be ≥ 2 cm;
  3. Availability of pathology slides along with baseline clinical, biological, and pathological features.

Exclusion criteria

Exclusion Criteria:

  1. Tissue sections obtained from biopsy specimens;
  2. Absence of viable tumor tissue in metastatic lesions;
  3. Lesions previously treated with ablation followed by surgical resection, resulting in inadequate tissue slide quality.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
431 participants (actual)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Surgical pathology slides from the SAHSYSU, 1,994 WSIs from 297 slides dated July 3, 2013.

    This group includes 297 patients with colorectal cancer liver metastasis (CRLM), from which 1,994 whole slide images (WSIs) were collected. These slides were used for developing and testing the COFFEE AI model for histopathological growth pattern (HGP) classification, providing valuable insights for tumor characterization and prognosis.

    Procedure: CRLM surgery

  • Surgical pathology slides from the SAHSYSU , 972 WSIs from 104 patients dated April 21, 2023.

    This cohort contains 104 patients diagnosed with CRLM. 972 WSIs were collected to validate the COFFEE model on a more recent dataset, evaluating the model's performance in both binary and four-class HGP classifications.

    Procedure: CRLM surgery

  • Surgical pathology slides from the SAHSYSU, 114 WSIs from 30 patients dated 2024.

    This prospective cohort consists of 30 patients with CRLM, from which 114 WSIs were obtained in 2024. The cohort was used to assess the clinical applicability of the COFFEE AI model through a prospective trial, comparing the diagnostic performance of pathologists with and without AI assistance.

    Procedure: CRLM surgery

Interventions

  • ProcedureCRLM surgery

    Surgical resection of colorectal cancer liver metastasis (CRLM) involves the removal of metastatic lesions from the liver. This procedure is aimed at improving survival rates and reducing tumor burden in patients diagnosed with CRLM. The resection is performed to treat liver metastasis, and clinical outcomes, such as progression-free survival (PFS) and overall survival (OS), are assessed post-surgery to determine treatment efficacy.

06

What researchers measure

Primary outcomes

  1. Classification Accuracy (%) of the COFFEE AI Model in Binary Identification of Histopathological Growth Patterns (HGPs) in CRLM Using Whole Slide Images

    This outcome measures the diagnostic classification accuracy of the COFFEE AI model in detecting histopathological growth patterns (HGPs) in patients with colorectal cancer liver metastasis (CRLM). Accuracy is defined as the proportion of correctly predicted HGP labels compared to the ground truth labels determined by consensus of expert pathologists. The analysis includes binary classification (desmoplastic vs. non-desmoplastic). Accuracy will be calculated as: Accuracy = Total number of predictions / Number of correct predictions×100%. The outcome will be assessed using digital whole slide images obtained from liver metastasis specimens collected during surgery. Model performance will be evaluated 6 months post-surgery in a prospective validation cohort.

    Time frame: 6 months post-surgery (for prospective cohort)

Secondary outcomes

  1. Classification Accuracy (%) of the COFFEE AI Model in Multi-Class Identification of Histopathological Growth Patterns (HGPs) in CRLM Using Whole Slide Images

    This outcome measures the diagnostic classification accuracy of the COFFEE AI model in detecting histopathological growth patterns (HGPs) in patients with colorectal cancer liver metastasis (CRLM). Accuracy is defined as the proportion of correctly predicted HGP labels compared to the ground truth labels determined by consensus of expert pathologists. The analysis includes four-class classification (desmoplastic, replacement, pushing, and mixed). Accuracy will be calculated as: Accuracy = Total number of predictions / Number of correct predictions×100%. The outcome will be assessed using digital whole slide images obtained from liver metastasis specimens collected during surgery. Model performance will be evaluated 6 months post-surgery in a prospective validation cohort.

    Time frame: 6 months post-surgery (for prospective cohort)

Other outcomes

  1. Progression-Free Survival (PFS, in months) in Colorectal Cancer Liver Metastasis (CRLM) Patients Stratified by AI-based Histopathological Growth Pattern (HGP) Classification

    This outcome evaluates the association between AI-based HGP classification (desmoplastic and non-desmoplastic) and progression-free survival (PFS) in patients with colorectal cancer liver metastasis (CRLM) following curative-intent resection. PFS is defined as the time from surgery to disease progression or death from any cause. Kaplan-Meier analysis will be used to estimate PFS for each HGP group, with comparisons by log-rank test. Multivariate Cox regression models will assess the prognostic value of HGPs, adjusting for clinical covariates (e.g., age, sex, metastasis number/size, chemotherapy, margin status, tumor burden score). Hazard ratios with 95% confidence intervals will be reported. Model assumptions will be tested and adjusted if necessary.

    Time frame: Up to 3 years post-surgery

  2. Overall Survival (OS, in months) in Colorectal Cancer Liver Metastasis (CRLM) Patients Stratified by AI-based Histopathological Growth Pattern (HGP) Classification

    This outcome evaluates the association between AI-based HGP classification (desmoplastic and non-desmoplastic) and overall survival (OS) in patients with colorectal cancer liver metastasis (CRLM) following curative-intent resection. OS is defined as the time from surgery to death from any cause. Kaplan-Meier analysis will be used to estimate OS for each HGP group, with comparisons by log-rank test. Multivariate Cox regression models will assess the prognostic value of HGPs, adjusting for clinical covariates (e.g., age, sex, metastasis number/size, chemotherapy, margin status, tumor burden score). Hazard ratios with 95% confidence intervals will be reported. Model assumptions will be tested and adjusted if necessary.

    Time frame: Up to 3 years post-surgery

  3. Time to Diagnosis (in minutes) by Pathologists With and Without AI-Assisted COFFEE Model in CRLM HGP Classification

    This outcome assesses the impact of the AI-assisted COFFEE model on diagnostic efficiency by comparing the time required by pathologists to classify histopathological growth patterns (HGPs) of colorectal cancer liver metastasis (CRLM), with and without COFFEE assistance. The metric is the time (minutes) from slide review start to final diagnosis, measured for each pathologist using a standardized digital whole slide image platform. The comparison includes two arms: the AI-assisted diagnosis arm, where junior pathologists use COFFEE as a decision-support tool, and the conventional diagnosis arm, where pathologists perform manual classification based on visual histopathological assessment. All participants review the same set of slides in randomized order, and diagnostic time is logged by the viewing software. Descriptive statistics (median, IQR) will be reported.

    Time frame: During the prospective trial period (6 months)

  4. Diagnostic Accuracy (percentage of correct classifications) of Pathologists With and Without AI-Assisted COFFEE Model in CRLM HGP Classification

    This outcome evaluates the diagnostic accuracy of pathologists in classifying histopathological growth patterns (HGPs) of colorectal cancer liver metastasis (CRLM), comparing AI-assisted versus conventional diagnostic workflows. Accuracy is defined as the proportion of correctly classified whole slide images (WSIs) relative to a gold-standard consensus diagnosis by expert gastrointestinal pathologists. Each pathologist will independently classify the same set of CRLM WSIs under two conditions: with AI assistance (COFFEE model) and without AI assistance (manual assessment). Classification will be evaluated for both binary HGP categories (desmoplastic vs. non-desmoplastic) and four-class HGP categories (desmoplastic, replacement, pushing, mixed). Accuracy will be calculated as: Accuracy = Total number of predictions / Number of correct predictions×100%.

    Time frame: During the prospective trial period (6 months)

07

Study locations

1 site
  • Ethics Committee of the Sixth Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510655, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06936098
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Responsible party
Yunfang Yu (Attending Physician, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Apr 20, 2025
Start date
May 22, 2023
Primary completion
Mar 6, 2024
Completion
Mar 6, 2024
Last update
Apr 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion